520 Rec'd PCT/P

FORM PTO-1390 (Modified) (REV 10-95)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

1038-1003 MIS:jb

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/462816

INTERNATIONAL APPLICATION NO. PCT/CA98/00697

INTERNATIONAL FILING DATE 16 July 1998

PRIORITY DATE CLAIMED 18 July 1997

TITLE OF INVENTION

NUCLEIC ACID VACCINES ENCODING G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS

		C(S) FOR DO/EO/US Li; Suryprakash Sambhara; and Michel H. Klein
Appli	cant h	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1.	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.		A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
		a. is transmitted herewith (required only if not transmitted by the International Bureau).
		b. 🛮 has been transmitted by the International Bureau.
		c. \square is not required, as the application was filed in the United States Receiving Office (RO/US).
6.		A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.		A copy of the International Search Report (PCT/ISA/210).
8.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
		a. are transmitted herewith (required only if not transmitted by the International Bureau).
		b. 🛮 have been transmitted by the International Bureau.
		c. \square have not been made; however, the time limit for making such amendments has NOT expired.
		d. \square have not been made and will not be made.
9.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10.	\boxtimes	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4))unsigned copy
11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
It	tems 1	3 to 18 below concern document(s) or information included:
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.	\boxtimes	A FIRST preliminary amendment.
		A SECOND or SUBSEQUENT preliminary amendment.
16.		A substitute specification.
17.		A change of power of attorney and/or address letter.
18.		Certificate of Mailing by Express Mail
19.	\boxtimes	Other items or information:
		Sequence Listing on comupter-readable and on printed paper forms. It is hereby stated that the Sequence Listing contained on the computer disk is the same as the Sequence Listing in printed paper form.

430 Rec'd PCT/PTO U.S. APPLICATION NO. (P INTERNATIONAL APPLICATION 1 PCT/CA98/00697 1038-1003 MIS:jb 20. The following fees are submitted:. CALCULATIONS PTO USE ONLY BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): \$840.00 Search Report has been prepared by the EPO or JPO International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO \$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$970.00 Surcharge of \$130.00 for furnishing the oath or declaration later than \$0.00 months from the earliest claimed priority date (37 CFR 1.492 (e)). NUMBER FILED NUMBER EXTRA RATE **CLAIMS** 28 \$18.00 \$504.00 -20 =Total claims 5 \$78.00 \$390.00 8 - 3 = Independent claims \$0.00 Multiple Dependent Claims (check if applicable). \$1,864.00 TOTAL OF ABOVE CALCULATIONS Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). \$0.00 **SUBTOTAL** \$1,864.00 Processing fee of \$130.00 for furnishing the English translation later than □ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). \$0.00 TOTAL NATIONAL FEE \$1,864.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). \$0.00 TOTAL FEES ENCLOSED \$1,864.00 Amount to be: refunded \$ charged X to cover the above fees is enclosed. A check in the amount of \$1,864.00 in the amount of to cover the above fees. Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment 19-2253 A duplicate copy of this sheet is enclosed. to Deposit Account No. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: Michael I. Stewart Sim & McBurney Michael I. Stewart 6th Floor, 330 University Avenue NAME Toronto, Ontario Canada, M5G 1R7. 24,973 REGISTRATION NUMBER January 13, 2000

DATE

09/462816 430 Rec'd PCT/PTO 14 JAN 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Our Ref: 1038-1003 MIS:jb

In re National Phase of International Application

No.:

PCT/CA98/00697

International

Filing Date:

July 16, 1998

Applicant:

Xiaomao Li, et al.

Title:

NUCLEIC ACID VACCINES ENCODING G PROTEIN OF

RESPIRATORY SYNCYTIAL VIRUS

PRELIMINARY AMENDMENT

The Commissioner of Patents and Trademarks, Washington, D.C. 20231, U. S. A.

Dear Sir:

Please amend this application in the following manner:

In the Disclosure:

Before the first line of the specification, add the following:

REFERENCE TO RELATED APPLICATIONS

This application is a national phase application under 35 U.S.C. 371 of PCT/CA98/00697."

REMARKS

The specification has been amended on page 1 to reflect that this application is a U.S. National Phase filing under 35 U.S.C. 371 of PCT/CA98/00697.

Respectfully submitted,

Michael I. Stewart Reg. No. 24,973

Toronto, Ontario, Canada (416) 595-1155 FAX No. (416) 595-1163

Date: January 13, 2000

09/462816 Rec'd PCT/PTO _1 4 JAN 2000

TITLE OF INVENTION

NUCLEIC ACID VACCINES ENCODING G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS

5

FIELD OF INVENTION

The present invention is related to the field of respiratory syncytial virus (RSV) vaccines and is particularly concerned with vaccines comprising nucleic 10 acid sequences encoding the attachment (G) protein of RSV.

BACKGROUND OF INVENTION

Respiratory syncytial virus (RSV), a negativestrand RNA virus belonging to the Paramyxoviridae family 15 of viruses, is the major viral pathogen responsible for bronchiolitis and pneumonia in infants and young children (ref. 1 - Throughout this application, various references are referred to in parenthesis to more fully describe the state of the art to which this invention 20 pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Acute respiratory tract 25 infections caused by RSV result in approximately 90,000 hospitalizations and 4,500 deaths per year in the United States (ref. 2). Medical care costs due to RSV infection are greater than \$340 M annually in the United There is currently no licensed States alone (ref. 3). 30 vaccine against RSV. The main approaches for developing an RSV vaccine have included inactivated virus, liveattenuated viruses and subunit vaccines.

A protective immune response against RSV is thought to require the induction of neutralizing antibodies against the surface fusion (F) and attachment (G) glycoproteins (ref. 4). In addition, cytotoxic T lymphocytes (CTL) responses are involved in viral clearance. The F protein is conserved amongst the RSV A

and B subgroups.

The G protein (33 kDa) of RSV is heavily O-glycosylated giving rise to a glycoprotein of apparent molecular weight of 90 kDa (ref. 5). Two broad subtypes of RS virus have been defined: A and B (ref. 6). The major antigenic differences between these subtypes are found in the G glycoprotein (refs. 3, 7).

2

The use of RSV proteins as vaccines may have obstacles. Parenterally administered vaccine candidates 10 have so far proven to be poorly immunogenic with regard to the induction of neutralizing antibodies seronegative chimpanzees. The serum antibody response induced by these antigens may be further diminished in the presence of passively acquired antibodies, such as 15 the transplacentally acquired maternal antibodies which most young infants possess. A subunit vaccine candidate for RSV consisting of purified fusion (F) glycoprotein from RSV infected cell cultures and purified immunoaffinity or ion-exchange chromatography has been 20 described (ref. 8). Parenteral immunization seronegative or seropositive chimpanzees with this preparation was performed and three doses of 50 μg were required in seronegative animals to induce an RSV serum neutralizing titre of approximately 1:50. 25 subsequent challenge of these animals with wild-type RSV, no effect of immunization on virus shedding or clinical disease could be detected in the upper respiratory tract. The effect of immunization with this vaccine on virus shedding in the lower respiratory tract 30 was not investigated, although this is the site where the serum antibody induced by parenteral immunization may be expected to have its greatest effect. Safety and immunogenicity studies have been performed in a small The vaccine was number of seropositive individuals. 35 found to be safe in seropositive children and in three

seronegative children (all > 2.4 years of age). The effects of immunization on lower respiratory tract disease could not be determined because of the small number of children immunized. One immunizing dose in 5 seropositive children induced a 4-fold increase in virus neutralizing antibody titres in 40 to 60% of vaccinees. Thus, insufficient information is available from these small studies to evaluate the efficacy of this vaccine against RSV-induced disease. A further 10 problem facing subunit RSV vaccines is the possibility inoculation of seronegative subjects that might result in immunogenic preparations enhancement. In the 1960's, vaccination of infants with a formalin-inactivated RSV preparation (FI-RSV) resulted 15 in enhanced lung disease upon subsequent exposure to live virus, also referred to as immunopotentiation These vaccinees developed strong (refs. 9, 10). serological responses, but were not protected against infection and some developed severe, occasionally fatal 20 respiratory tract disease upon natural infection. Although precise mechanisms remain unknown, it has been suggested that this form of immune enhancement might reflect either structural alterations of RSV antigens (ref. 11), residual serum and/or cellular contaminants 25 (ref. 12), a specific property of the viral attachment (G) protein (refs. 13,14) or an imbalanced cell-mediated immune response (refs. 13,15). It has been demonstrated that the FI-RSV vaccine induced a TH2-type immune response in mice whereas immunization with live RSV, 30 which does not cause immunopotentiation, elicits a TH1 response (ref.15).

In some studies, the immune response to immunization with a synthetic RSV FG fusion protein resulted in disease enhancement in rodents resembling that induced by a formalin-inactivated RSV vaccine.

Immunization of mice with a recombinant vaccinia virus expressing the RSV G protein resulted in G-specific T cell responses in the lungs which are exclusively recruited from the CD4+T cell sublineage and are strongly Th2-biased. G-specific T cells induce lung haemmorrage, pulmonary neutrophil recruitment (shock lung), intense pulmonary eosinophilia, and sometimes death in the adoptively transferred murine recipients (ref. 14). The association of immunization with disease enhancement using certain vaccine preparations including non-replicating antigens suggests caution in their use as vaccines in seronegative humans.

Live attenuated vaccines against disease caused by RSV may be promising for two main reasons. 15 infection by a live vaccine virus induces a balanced immune response comprising mucosal and serum antibodies and cytotoxic T-lymphocytes. Secondly, infection of infants with live attenuated vaccine candidates or naturally acquired wild-type virus is not associated 20 with enhanced disease upon subsequent reinfection. It will be challenging to produce live attenuated vaccines that are immunogenic for younger infants who possess maternal virus-neutralizing antibodies and yet are attenuated for seronegative 25 infants greater than or equal to 6 months of age. Attenuated live virus vaccines also have the risks of residual virulence and genetic instability.

Injection of plasmid DNA containing sequences encoding a foreign protein has been shown to result in expression of the foreign protein and the induction of antibody and cytotoxic T-lymphocyte (CTL) responses to the antigen in a number of studies (see, for example, refs. 16, 17, 18). The use of plasmid DNA inoculation to express viral proteins for the purpose of immunization may offer several advantages over the

20 extrinsic adjuvant.

strategies summarized above. Firstly, DNA encoding a viral antigen can be introduced in the presence of antibody to the virus itself, without loss of potency due to neutralization of virus by the antibodies.

- 5 Secondly, the antigen expressed in vivo should exhibit a native conformation and the appropriate glycosylation. Therefore, the antigen should induce an response similar to that induced by the antigen present in the wild-type virus infection. In contrast, some 10 processes used in purification of proteins can induce conformational changes which may result in the loss of immunogenicity of protective epitopes and possibly immunopotentiation. Thirdly, the expression of proteins from injected plasmid DNAs can be detected in vivo for a 15 considerably longer period of time than that in virusinfected cells, and this has the theoretical advantage of prolonged cytotoxic T-cell induction and enhanced antibody responses. Fourthly, in vivo expression of antigen may provide protection without the need for an
- The ability to immunize against disease caused by RSV by administration of a DNA molecule encoding an RSV G protein was unknown before the present invention. particular, the efficacy of immunization against RSV 25 induced disease using a gene encoding a secreted form of the RSV G protein was unknown. Infection with RSV leads to serious disease. It would be useful and desirable to provide isolated genes encoding RSV G protein and nonreplicating vectors, including plasmid vectors, for in 30 vivo administration and for use in immunogenic preparations, including vaccines, for protection against disease caused by RSV and for the generation of diagnostic reagents and kits. In particular, it would be desirable to provide vaccines that are immunogenic 35 and protective in humans, including seronegative

infants, that do not cause disease enhancement (immunopotentiation).

SUMMARY OF INVENTION

The present invention relates to a method of immunizing a host against disease caused by respiratory syncytial virus, to non-replicating vectors containing nucleic acid molecules used in immunogenic compositions for such purpose, and to diagnostic procedures utilizing the vectors and nucleic acid molecules. In particular, the present invention is directed towards the provision of nucleic acid vaccines encoding the G protein of respiratory syncytial virus.

In accordance with one aspect of the invention, there is provided an immunogenic composition for in vivo administration to a host for the generation in the host of protective antibodies to respiratory syncytial virus (RSV) G protein, comprising a non-replicating vector comprising:

- a first nucleotide sequence encoding a RSV G 20 protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein,
 - a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and
- a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host, and
 - a pharmaceutically-acceptable carrier therefor.
- The first nucleotide sequence may be that which encodes a full-length RSV G protein. The first nucleotide sequence may comprise the nucleotide sequence shown in Figure 2 (SEQ. ID No: 1) or encode a full length RSV G protein having the amino acid sequence 35 shown in Figure 2 (SEQ. ID no: 2).

Alternatively, the first nucleotide sequence may be that which encodes an RSV G protein from which the transmembrane coding sequence and sequences upstream thereof are absent. The first nucleotide sequence 5 encoding the truncated RSV G protein may comprise the nucleotide sequence shown in Figure 3 (SEQ. ID no: 3) or may comprise a nucleotide sequence encoding the truncated RSV G protein having the amino acid sequence shown in Figure 3 (SEQ ID no: 4). The lack of expression of the transmembrane region results in a secreted form of the RSV G protein.

The non-replicating vector may further comprise a heterologous signal peptide encoding nucleotide sequence immediately upstream of the 5'-terminus of the first nucleotide sequence. The signal peptide encoding sequence may encode the signal peptide of human tissue plasminogen activator.

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The second nucleotide sequence may comprise the human cytomegalovirus Intron A.

The non-replicating vector generally is a plasmid vector. Plasmid vectors encoding the G protein and included in the immunogenic composition provided by this aspect of the invention may specifically be pXL5 or pXL6, constructed and having their characterizing elements, as seen in Figures 4 or 5, respectively.

In accordance with a further aspect of the present invention, there is provided a method of immunizing a 30 host against disease caused by infection with respiratory syncytial virus (RSV), which comprises administering to the host an effective amount of a non-replicating vector comprising:

a first nucleotide sequence encoding an RSV G $_{
m 35}$ protein or a RSV G protein fragment that generates

antibodies that specifically react with RSV G protein,

a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and

a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein *in vivo* from said vector in the host.

The immunization method may be effected to induce a 10 balanced Th1/Th2 immune response.

The present invention also includes a novel method of using a gene encoding respiratory syncytial virus (RSV) G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating the gene;

operatively linking the gene to at least one control sequence to produce a non-replicating vector, said control sequence directing expression of the RSV G protein when said vector is introduced into a host to produce an immune response to the RSV G protein, and

introducing the vector into the host.

25 The procedure provided in accordance with this aspect of the invention may further include the step of:

operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV G protein in the host,

30 preferably by introducing the immunoprotection enhancing sequence between the control sequence and the gene, including introducing immunostimulatory CpG sequences in the vector.

In addition, the present invention includes a 35 method of producing a vaccine for protection of a host

35

against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first nucleotide sequence encoding an RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein,

operatively linking the first nucleotide sequence to at least one control sequence to produce a non-replicating vector, the control sequence directing expression of the RSV G protein when introduced into a lost to produce an immune response to the RSV G protein when expressed in vivo from the vector in a host,

operatively linking the first nucleotide sequence to a second nucleotide sequence to increase expression of the RSV G protein in vivo from the vector in a host, and

formulating the vector as a vaccine for *in vivo* administration.

The vector may be a plasmid vector selected from pXL5 and pXL6. The invention further includes a vaccine 20 for administration to a host, including a human host, produced by this method.

As noted previously, the vectors provided herein are useful in diagnostic applications. In a further aspect of the invention, therefore, there is provided a method of determining the presence of a respiratory syncytial virus (RSV) G protein in a sample, comprising the steps of:

(a) immunizing a host with a non-replicating vector to produce antibodies specific for the RSV G protein, the non-replicating vector comprising a first nucleotide sequence encoding an RSV G protein or an RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to the first nucleotide sequence for expression of the

10

RSV G protein in the host and a second nucleotide located between the first nucleotide sequence and the promoter sequence to increase expression of the RSV G protein in vivo from the vector in the host;

- (b) isolating the RSV G protein-specific antibodies;
- contacting the sample with the antibodies to produce complexes comprising any RSV ${\tt G}$ protein present in the sample and the RSV ${\tt G}$ protein-specific antibodies; and
- determining production of the complexes. non-replicating vector employed to elicit antibodies may be a plasmid vector pXL5 or pXL6.
- 15 The invention also includes a diagnostic kit for detecting the presence of a respiratory syncytial virus (RSV) G protein in a sample, comprising:

a

- non-replicating vector capable generating antibodies specific for the 20 protein when administered to a host, said nonreplicating vector comprises a first nucleotide sequence encoding an RSV G protein or an RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter 25 sequence operatively coupled to the nucleotide sequence for expression of the RSV G protein in a host, and a second nucleotide sequence located between the first nucleotide sequence and the promoter sequence to increase expression of the 30 RSV G protein in vivo from the vector in the host;
 - isolation means to isolate the RSV G protein specific antibodies:
- contacting means to contact the isolated RSV G protein-specific antibodies with the sample to produce a complex comprising any RSV G protein 35

15

present in the sample and RSV G protein specific antibodies; and

- (d) identifying means to determine production of the complex.
- The present invention further is directed to a method for producing antibodies specific for a G protein of a respiratory syncytial virus (RSV) comprising:
 - (a) immunizing a host with an effective amount of a non-replicating vector to produce RSV G-specific antibodies, said non-replicating vector comprising:
 - a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein,
 - a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and
- a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host; and
 - (b) isolating the RSV G specific antibodies from the host.
- The present invention is also directed to a method for producing monoclonal antibodies specific for a G protein of respiratory syncytial virus (RSV), comprising the steps of:
- (a) constructing a vector comprising a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, a promoter sequence operatively coupled to the first nucleotide sequence for expression of the RSV G protein in the host and a second nucleotide

sequence located between the first nucleotide sequence and the promoter sequence to increase expression of the RSV G protein when *in vivo* from the vector in a host;

- (b) administering the vector to at least one mouse to produce at least one immunized mouse;
 - (c) removing B-lymphocytes from the at least one immunized mouse;
- (d) fusing the B-lymphocytes from the at least one immunized mouse with myeloma cells, thereby producing hybridomas;
 - (e) cloning the hybridomas;
 - (f) selecting clones which produce anti-RSV G
 protein antibody;
- (g) culturing the anti-RSV G protein antibody-producing clones; and
 - (h) isolating anti-RSV G protein monoclonal antibodies.

Such monoclonal antibodies may be used to purify RSV G 20 protein from virus.

In this application, the term "RSV G protein" is used to define a full-length RSV G protein, such proteins having variations in their amino acid sequences including those naturally occurring in various strains

- of RSV, a secreted form of RSV G protein lacking a transmembrane region, as well as functional analogs of the RSV G protein. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has
- 30 the same function as the second protein. The functional analog may be, for example, an immunologically-active fragment of the protein or an immunologically-active substitution, addition or deletion mutant thereof.

PCT/CA98/00697 WO 99/04010

BRIEF DESCRIPTION OF THE FIGURES

13

The present invention will be further understood from the following General Description and Examples with reference to the Figures of the accompanying drawings, 5 in which:

Figure 1 illustrates a restriction map of the gene encoding a G protein of respiratory syncytial virus (RSV):

Figure 2 illustrates the nucleotide sequence of a 10 gene encoding a membrane bound form of the G protein of respiratory syncytial virus (SEQ ID No: 1) as well as the amino acid sequence of the RSV G protein encoded thereby (SEQ ID No: 2);

Figure 3 illustrates the nucleotide sequence of a 15 gene encoding the secreted form of the RSV G protein lacking the transmembrane domain (SEQ ID No: 3) as well as the amino acid sequence of a truncated RSV G protein lacking the transmembrane domain encoded thereby (SEQ ID No: 4);

20 Figure 4 shows the construction of plasmid pXL5 containing a gene encoding a full-length membrane attached form of the RSV G protein and containing the CMV Intron A sequence;

Figure 5 shows the construction of plasmid pXL6 25 containing a gene encoding a secreted form of the RSV G protein lacking the transmembrane domain and containing the CMV Intron A sequence as well as a nucleotide sequence encoding a signal peptide of the human tissue plasminogen activator (TPA);

30 Figure 6 shows the nucleotide sequence for the plasmid VR-1012 (SEQ ID No. 5);

Figure 7 shows the nucleotide sequence for the 5' untranslated region and the signal peptide of the human tissue plasminogen activator (TPA) (SEQ. ID no: 6) and

Figure 8 shows the lung cytokine expression profile 35

in DNA immunized mice after RSV challenge.

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention relates generally to polynucleotide, including DNA, immunization 5 to obtain protection against infection by respiratory syncytial virus (RSV) and to diagnostic procedures using particular non-replicating vectors. In the present invention, several recombinant plasmid vectors were constructed to contain a nucleotide sequence encoding an 10 RSV G protein.

The nucleotide sequence of the full length RSV G gene is shown in Figure 2 (SEQ ID No: 1). Certain constructs provided herein include the nucleotide sequence encoding the full-length RSV G (SEQ ID No: 2) protein while others include an RSV G gene modified by deletion of the transmembrane coding sequence and nucleotides upstream thereof (see Figure 3, SEQ ID No: 3), to produce a secreted or truncated RSV G protein lacking the transmembrane domain (SEQ ID No. 4).

The nucleotide sequence encoding the RSV G protein is operatively coupled to a promoter sequence for expression of the encoded RSV G protein in vivo. The promoter sequence may be the human immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 19. Any other convenient promoter may be used, including constitutive promoters, such as, the Rous Sarcoma Virus LTRs, and inducible promoters, such as the metallothionin promoter, and tissue specific promoters.

The non-replicating vectors provided herein, when administered to an animal in the form of an immunogenic composition with a pharmaceutically-acceptable carrier, effect in vivo RSV G protein expression, as demonstrated by an antibody response in the animal to which it is administered. Such antibodies may be used herein in the

20 A sequence.

detection of RSV protein in a sample, as described in more detail below. The administration of the non-replicating vectors, specifically plasmids pXL5 and pXL6, produced anti-G antibodies, virus neutralizing antibodies, a balanced Th1/Th2 response in the lungs post viral challenge and conferred protection in mice against live RSV infection, as seen from the Examples below.

The recombinant vector also may include a second 10 nucleotide sequence located adjacent the RSV G protein encoding nucleotide sequence to enhance immunoprotective ability of the RSV G protein when expressed in vivo in a host. Such enhancement may be provided by increased in vivo expression, for example, 15 by increased mRNA stability, enhanced transcription and/or translation. This additional sequence generally is located between the promoter sequence and the RSV G protein-encoding sequence. This enhancement sequence may comprise the immediate early cytomegalovirus Intron

The non-replicating vector provided herein may also comprise an additional nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent,

such as a cytokine. Such vector may contain the additional nucleotide sequence in a chimeric or a bicistronic structure. Alternatively, vectors containing the additional nucleotide sequence may be separately constructed and coadministered to a host, along with the non-replicating vectors provided herein.

The non-replicating vector may further comprise a nucleotide sequence encoding a heterologous viral or eukaryotic signal peptide, such as the human tissue plasminogen activator (TPA) signal peptide, in place of the endogenous signal peptide for the truncated RSV G

protein. Such nucleotide sequence may be located immediately upstream of the RSV G encoding sequence in the vector.

The immunogenicity of the non-replicating DNA 5 vectors may be enhanced by inserting immunostimulatory CpG sequences in the vector.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, 10 diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as 15 vaccines, may be prepared from the RSV G genes and The vaccine elicits an vectors as disclosed herein. an animal which includes immune response in production of anti-RSV G antibodies. Immunogenic compositions, including vaccines, containing the nucleic 20 acid may be prepared as injectables, in physiologicallysolutions emulsions acceptable liquid or polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid 25 liposome (for example, as described in WO 9324640, ref. 20) or the nucleic acid may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with polyanions, such as DNA and RNA, resulting 30 in liposome/nucleic acid complexes that capture up to addition, of the polynucleotide. In the with cell polycationic complexes fuse resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal 35 compartment. Published PCT application WO 94/27435

PCT/CA98/00697 WO 99/04010

immunization describes compositions for genetic comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other 5 transfection facilitating agents, may advantageously be used.

17

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 10 describes а particulate carrier of phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the 15 layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the trinitrophenylated keyhole limpet antigens hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactideco-glycolide). Other polymers for 20 encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-coglycolide), copolyoxalates, poly(lactide-co-caprolactone), polycaprolactone, poly(esteramides), polyorthoesters and poly(8hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a 25 delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. delivery vehicle is particularly intended for the uptake 30 of vaccine across the nasal mucosae. The delivery vehicle may additionally contain an absorption enhancer.

The RSV G gene containing non-replicating vectors may be mixed with pharmaceutically acceptable excipients which are compatible therewith. Such excipients may 35 include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof.

- 5 Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site with a local anesthetic. Alternatively, the immunogenic
- compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to mucosal surfaces by, for example, the nasal or oral
- 15 (intragastric) routes. Alternatively, other modes of administration including suppositories and formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols or triglycerides.
- formulations may include normally employed incipients, such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

immunogenic preparations and vaccines administered in a manner compatible with the dosage 25 formulation, and in such amount will therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV G 30 protein and antibodies thereto, and if needed, produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. suitable dosage ranges are readily determinable by one 35 skilled in the art and may be of the order of about 1 μg to about 2 mg of the RSV G gene-containing vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations.

- 5 The dosage may also depend on the route administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are 10 combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.
- Immunogenicity can be significantly improved if the vectors are co-administered with adjuvants, commonly used as 0.05 to 0.1 percent solution in phosphate-buffered saline. Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses.

Immunostimulatory agents or adjuvants have been used for many years to improve the host immune responses to, for example, vaccines. Thus, adjuvants have been identified that enhance the immune response to antigens. Some of these adjuvants are toxic, however, and can cause undesirable side-effects, making them unsuitable for use in humans and many animals. Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as

adjuvants in human and veterinary vaccines.

A wide range of extrinsic adjuvants and other immunomodulating material can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens to produce immune stimulating complexes (ISCOMS), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as monophoryl lipid A, QS 21 and polyphosphazene.

In particular embodiments of the present invention, the non-replicating vector comprising a first nucleotide sequence encoding an G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

The immunogenicity of the non-replicating vector may be enhanced by coadministering plasmid DNA vectors expressing cytokines or chemokines or by coexpressing such molecules in a bis-cistronic or fusion construct.

The non-replicating vector may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 21) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH antibodies in the mice, while Furth et al. (ref. 22) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

30 2. Immunoassays

The RSV G genes and vectors of the present invention are useful as immunogens for the generation of anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or

procedures known in the art. In ELISA assays, the nonreplicating vector first is administered to a host to generate antibodies specific to the RSV G protein. These RSV G-specific antibodies are immobilized onto a 5 selected surface, for example, a surface capable of binding the antibodies, such as the wells of polystyrene microtiter plate. After washing to remove unadsorbed antibodies, a non-specific protein, such as a solution of bovine serum albumin (BSA) that is known to 10 be antigenically neutral with regard to the test sample, may be bound to the selected surface. This allows for blocking of non-specific adsorption sites immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the 15 surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be in a manner conducive to immune complex (antigen/antibody) formation. This procedure 20 include diluting the sample with diluents, solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. 25 Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. formation of specific immunocomplexes between the test 30 sample and the bound RSV G specific antibodies, and subsequent washing, the occurrence, and even amount, of

BIOLOGICAL MATERIALS

Certain plasmids that contain the gene encoding the 35 RSV G protein and referred to herein have been deposited

immunocomplex formation may be determined.

with the American Type Culture Collection (ATCC) located at 12301 Parklawn Drive, Rockville, Maryland, 20852, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

5 Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed at that time. Samples of the deposited plasmids will be 10 replaced if the depository is unable to dispense viable samples. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only illustration of the invention. Any equivalent or15 similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of the invention.

	Plasmid	ATCC Designation	<u>Date</u>	Depo	sited
	pXL5	209143	July	16,	1997
20	pXL6	209144	July	16,	1997

EXAMPLES

The above disclosure generally describes present invention. A more complete understanding can be obtained by reference to the following 25 Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated circumstances may suggest or render expedient. Although 30 specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry, and immunology used but not explicitly 35 described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

Example 1

This Example describes the construction of vectors 5 containing the RSV G gene.

Figure 1 shows a restriction map of the gene encoding the G protein of respiratory syncytial virus and Figure 2 shows the nucleotide sequence of the gene encoding the full-length RSV G protein (SEQ ID No: 1) and the deduced amino acid sequence (SEQ ID No: 2).

Figure 3 shows the gene encoding the secreted RSV G protein (SEQ ID No: 3) and the deduced amino acid sequence (SEQ ID No: 4).

Plasmid pXL5 (Figure 4) was prepared for the 15 expression of the full-length RSV G protein as follows:

recombinant Bluescript plasmid (RSV containing the cDNA encoding the full-length G protein of a clinical RSV isolate (subgroup A) was used to construct vectors for RSV DNA-G immunization. RSV G12 20 was digested with AflIII and EcoRI and filled-in with the Klenow subunit of DNA polymerase. The resulting 1.23 kb fragment containing the coding sequence for the full-length G protein was gel-purified and ligated to VR-1012 (Vical) (Figure 6) previously linearized with 25 EcoRV. This procedure placed the RSV G cDNA downstream of the immediate-early cytomegalovirus (CMV) promoter and Intron A sequences of human cytomegalovirus (CMV) and upstream of the bovine growth hormone (BGH) poly-A site. The junctions of the cDNA fragments in the plasmid

30 construct were confirmed by sequencing analysis. The resulting plasmid was designated pXL5.

Plasmid pXL6 (Figure 5) was prepared for the expression of a secretory RSV G protein as follows:

RSV G12 was digested with EcoRI, filled-in with 35 Klenow and digested again with BamHI. The BamHI

cleavage resulted in the generation of a cDNA fragment encoding a RSV G protein with N-terminal truncation. This DNA segment was gel-purified and ligated in the presence of a pair of 11 mer oligodeoxynucleotides 5 (5'GATCCACTCAG 3') (SEQ ID no: 7)

3' GTGAGTCCTAG 5' (SEQ ID no: 8) to VR-1020 (Vical) previously digested with BglII, filled in with Klenow, digested again with BamHI and gel-purified. This procedure placed the truncated RSV G 10 cDNA (lacking the coding region for the N-terminal 91 amino acid residues including the transmembrane domain) downstream of the immediate-early CMV promoter and Intron A sequences of human CMV and upstream of the BGH poly-A site. In addition, there was the introduction of 15 approximately 100 bp of 5' untranslated region and the coding sequence for the signal peptide of human plasminogen activator protein (Figure 7) fused in frame to the N-terminus of the RSV G protein coding sequence downstream of the CMV promoter/Intron A sequences. 20 junctions of the cDNA fragments in the plasmid construct were confirmed by sequencing analysis. The resulting plasmid was designated pXL6.

Example 2

This Example describes the immunization of mice.

25 Mice are susceptible to infection by RSV as described in ref. 24.

Plasmid DNA was purified through double CsCl centrifugations. For intramuscular (i.m.) immunization, tibialis anterior muscles of BALB/c mice (male, 6 to 8 week old) (Jackson Lab., Bar Harbor, ME, USA) were bilaterally injected with 2 x 50µg (1µg/µL in PBS) of either pXL5, pXL6 or V-1012. Five days prior to DNA injection, the muscles were treated with 2 x 50µL (10µM in PBS) of cardiotoxin (Latoxan, France) to increase DNA uptake and enhance immune responses, as reported by

Davis et al (ref. 23). The animals were boosted with the same dose of plasmid DNA 6 weeks and 13 weeks later, respectively. For intradermal (i.d.) immunization, 100µg of the plasmid DNA (2µg/µL in PBS) of were 5 injected at the base of the tail and boosted 6 weeks and 13 weeks later, respectively. Mice in the positive control group were immunized intranasally (i.n.) with 10⁶ plaque forming units (pfu) of a clinical RSV strain of the A2 subtype grown in Hep2 cells kindly provided by 10 Dr. B. Graham (ref. 24).

Four weeks after the third immunization, mice were challenged intranasally with 10° pfu of the RSV A2 strain. Lungs were asceptically removed 4 days later, weighed and homogenized in 2 mL of complete culture medium (ref. 25). The number of pfu in lung homogenates was determined in duplicate as previously described (ref. 26) using vaccine-quality Vero cells.

Example 3

This Example describes the immunogenicity and 20 protection by polynucleotide immunization.

Antisera obtained from immunized mice were analyzed for anti-RSV G IgG antibody titres using specific enzyme-linked immunosorbent assay (ELISA) and for RSVspecific plaque-reduction titres. ELISAs were performed 25 using 96-well plates coated with immunoaffinity-purified RSV G protein (50 ng/mL) and 2-fold serial dilutions of immune sera. A goat anti-mouse IgG antibody conjugated alkaline phosphatase (Jackson ImmunoRes., Mississauga, Ontario, Canada) was used as secondary 30 antibody. Plaque reduction titres were determined according to Prince et al (ref. 26) using vaccinequality Vero cells. Four-fold serial dilutions of immune sera were incubated with 50 pfu of the RSV Long strain (ATCC) in culture medium at 37°C for 1 hr in the 35 presence of 5% CO2 and the mixtures were used to infect

Vero cells. Plaques were fixed with 80% methanol and developed 5 days later using a mouse anti-RSV F monoclonal IgG1 antibody and donkey anti-mouse IgG antibody conjugated to peroxidase (Jackson ImmunoRes., 5 Mississauga, Ontario, Canada). The RSV-specific plaque reduction titre was defined as the dilution of serum sample yielding 60% reduction in plaque number. Both ELISA and plaque reduction assays were performed in duplicate and data are expressed as the means of two determinations.

The results obtained are reproduced in Tables I and II below:

Table I. Immunogenicity of DNA-G in BALB/c Mice

Immunogen	Anti (Le	RSV-Specific Plaque Reduction		
Titre	6 weeks	10 weeks	17 weeks	(Log 2 titre) 17 weeks
VR-1012 (i.m.)	0.00 <u>+</u> 0.00	0.00 <u>+</u> 0.00	0.00 <u>+</u> 0.00	0.00 <u>+</u> 0.00
pXL5 (i.m.) pXL6 (i.m.)	3.10 ± 2.77 5.78 ± 1.20	9.70 ± 1.06 9.30 ± 0.82	8.60 ± 1.17 8.89 ± 1.54	5.40 ± 1.65 7.26 ± 0.82
pXL5 (i.d.) pXL6 (i.d.)	1.50 ± 1.27 3.70 ± 1.25	8.60 ± 1.43 10.30 ± 1.06	8.30 ± 1.25 9.44 ± 1.24	7.92 ± 0.59 6.92 ± 0.94
RSV (i.n.)	6.83 ± 0.41	9.67 <u>+</u> 0.52	9.83 ± 0.41	11.80 <u>+</u> 0.08

Table П. Immunoprotective Ability of DNA-G in BALB/c Mice

Immunogen	No. Mice	Mean Virus Lung Titre* (pfu/g lung) (Log 10 <u>+</u> SD)	No. Fully Protected Mice#
VR-1012 (i.m.)	6	4.81 <u>+</u> 0.01	0
pXL5 (i.m.)	6	0.29 ± 0.90	5
pXL6 (i.m.)	6	0.40 ± 1.20	5
pXL5 (i.d.)	6	0.30 ± 1.10	5
pXL6 (i.d.)	6	0.29 ± 0.90	5
RSV (i.n.).	6	0.00 <u>+</u> 0.00	6

^{*}Sensitivity of the assay: 10^{1.96} pfu/g lung.
The term, fully protected mice, refers to animals with no detectable RSV in the lungs 4 days post viral challenge.

As seen in Table I, plasmids pXL5 and pXL6 were found to be immunogenic following either i.m. or i.d. immunization producing anti-G antibodies and virus neutralizing antibodies. In addition, as seen in Table II, the plasmids pXL5 and pXL6 protected immunized mice against primary RSV infection of the lower respiratory tract. The control vector produced no immune response and did not confer protection.

Example 4

This Example describes the determination of the local lung cytokine expression profile in mice immunized with pXL5 and pXL6 after RSV challenge.

BALB/c mice were immunized at 0 and 6 weeks with 100µg of pXL5 and 6, prepared as described in Example 1, 15 and challenged with RSV i.n. at 10 weeks. animals were immunized with placebo PI-RSV and live RSV and challenged with RSV according to the same protocol. In addition, animals were immunized with pXL2, described in copending United States Patent Application 20 no. 08/476,397 filed June 7, 1995 (WO 96/40945) and challenged with RSV, also following the same protocol. Four days post viral challenge, lungs were removed from immunized mice and immediately frozen in nitrogen. Total RNA was prepared from lungs homogenized 25 in $TRIzol/\beta$ -mercaptoethanol by chloroform extraction and isopropanol precipitation. Reverse transcriptasepolymerase chain reaction (RT-PCR) was then carried out on the RNA samples using either IL-4, IL-5 or IFN- γ specific primers from CloneTech. The amplified products 30 were then liquid-hybridized to cytokine-specific 32Plabeled probes from CloneTech, resolved polyacrylamide gels and quantitated by scanning of the radioactive signals in the gels. Three mouse lungs were removed from each treatment group and analyzed for lung

35 cytokine expression for a minimum of two times.

20

25

30

data is presented in Figure 8 and represents the means and standard deviations of these determinations.

As may be seen from the data presented in Figure 8:

- 5 Immunization with live RSV intranasally (i.n.) resulted in a balanced cytokine profile (IFN- γ , ILand IL-5), whereas that with FI-RSV intramuscularly (i.m.) resulted in Th2 predominance (elevated IL-4 and IL-5). These 10 results are similar to those reported in the literature.
 - 2. Immunization with pXL5 or pXL6 via either the i.m. or intradermal (i.d.) route gave rise to a balanced cytokine profile similar to that with live RSV immunization.
 - 3. The magnitude of the cytokine responses with i.m. pXL6 (RSV G) and pXL2 (RSV F) immunization using the construct expressing a secretory form of the protein (SEC) is significantly higher than that with live RSV immunization.
 - 4. The magnitude of the cytokine response with pXL5 immunization using constructs expressing a full-length membrane-associated RSV G protein (MA) and i.d. pXL6 was somewhat higher than that with live RSV immunization.
 - 5. The balanced local cytokine response observed with DNA-G immunization contrasts with that reported by Openshaw et al (ref. 13). Using a recombinant vaccinia virus expressing the G protein, these investigators reported a local Th2 response by analysis of bronchoalveolar lavage.

The results herein, which were obtained through a monogenic approach, indicate that the Th2 response is not necessarily an intrinsic property of the G

35 protein.

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, the present invention provides certain novel non-replicating vectors containing genes encoding RSV G proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

REFERENCES

- McIntosh K., Canock, R.M. In: Fields B.N, Knipe,
 DM, editors. Virology. New York: Raven Press: 1990:
 1045-1072
- 2. Heilman, C.A., J. Infect. Dis. 1990, 161: 402 to 406.
- 3. Wertz GW, Sullender WM., Biotechnology 1992; 20: 151-176
- 4. Murphy, B. R. et al, 1994, Virus Res. 32: 13-36.
- 5. Levine, S., Kleiber-France, R., and Paradiso, P.R. (1987) J. Gen. Virol. 69, 2521-2524.
- 6. Anderson, L.J., Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernie, B.F., Stone, Y. and McIntosh, K. (1985) J. Infect. Dis. 151, 626-633.
- 7. Johnson et al., J. Virol 1987, 61: 3163-3166
- 8. Crowe, J.E., Vaccine 1995, 13: 415-421
- 9. Kapikian, A.Z. et al 1969, Am. J. Epidemiol. 89: 405-421.
- 10. Kim, H.W., et al 1969 Am. J. Epidemiol. 89: 422-434.
- 11. Murphy, B.R. et al 1986 J. Clin. Microbiol. 24: 197-202.
- 12. Vaux-Peretz, F. et al 1992 Vaccine 10: 113-118.
- 13. Openshaw, P.J. 1995 Springer-Semin Immunopathol. 17: 187-201.
- 14. Alwan et al 1994 J. Exp. Med. 179:81-89.
- 15. Graham, B.S. 1995 Am. J. Respir. Crit. Care Med. 152:563-6
- 16. WO 90/11092
- 17. WO 94/21797
- 18. Ulmer, Current Opinion, Invest Drugs, 1993, 2: 983-989
- 19. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., Nucl. Acids. Res. 1991, 19: 3979-3986.

- 20. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90: 11307-11311.
- 21. Tang et al., Nature 1992, 356: 152-154
- 22. Furth et al. Analytical Biochemistry, 1992, 205: 365-368
- 23. Davis et al., Vaccine 1994, 12: 1503-1509
- 24. Graham, B.S.; Perkins M.D.; Wright, P.F. and Karzon, D.T. J. Mod. Virol. 1988 26: 153-162.
- 25. Du, R.P et al. 1994., Bio Technology 12: 813-818.
- 26. Prince, G.A. et al, 1978. Ame. J. Pathol. 93: 771790.



34

CLAIMS

What we claim is:

 An immunogenic composition for in vivo administration to a host for the generation in the host of protective antibodies to respiratory syncytial virus (RSV) G protein, comprising a vector that will not replicate when introduced into the host to be protected comprising:

a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein.

a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and

a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host, and

a pharmaceutically-acceptable carrier therefor.

- 2. The composition of claim 1 wherein said first nucleotide sequence encodes a full-length RSV G protein.
- 3. The composition of claim 2 wherein said nucleotide sequence 20 comprises the nucleotide sequence shown in Figure 2 (SEQ ID NO:1).
 - 4. The composition of claim 2 wherein said first nucleotide sequence comprises the nucleotide sequence encoding a full length RSV G protein having the amino acid sequence shown in Figure 2 (SEQ ID NO:2).
- 5. The composition of claim 1 wherein said first nucleotide sequence encodes a RSV G protein from which the transmembrane coding sequence and sequences upstream thereto are absent.
 - 6. The composition of claim 5 wherein said vector further comprises a heterologous signal peptide encoding nucleotide sequence immediately upstream of the 5'-terminus of said first nucleotide sequence.
- 30 7. The composition of claim 6 wherein said signal peptide encoding sequence encodes the signal peptide for human tissue plasminogen activator.

- 8. The composition of claim 5 wherein said first nucleotide sequence comprises the nucleotide sequence shown in Figure 3 (SEQ ID NO:3).
- 9. The composition of claim 5 wherein said first nucleotide sequence 5 comprises a nucleotide sequence encoding a truncated RSV G protein having the amino acid sequence shown in Figure 3 (SEQ ID NO:4).
 - 10. The composition of claim 1 wherein said promoter sequence is an immediate early cytomegalovirus promoter.
- The composition of claim 1 wherein said second nucleotide sequence 11. 10 is the human cytomegalovirus Intron A.
 - 12. The composition of claim 1 wherein the vector is a plasmid vector.
 - 13. The composition of claim 12 wherein the plasmid vector is pXL5 as shown in Figure 4.
- 14. The composition of claim 12 wherein the plasmid vector is pXL6 as 15 shown in Figure 5.
 - A method of immunizing a host against disease caused by infection 15. with respiratory syncytial virus (RSV), which comprises administering to said host an effective amount of a vector that will not replicate when introduced into the host to be protected comprising:
- 20 a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein,
 - a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and
- a second nucleotide sequence located between said first nucleotide 25 sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host.
 - The method of claim 15 wherein said first nucleotide sequence encodes a full-length RSV G protein.
- The mothod of claim 16 wherein said nucleotide sequence comprises 36 17. the nucleotide sequence shown in Figure 2 (SEQ ID NO:1).

georing droing the hy- gains water, great, etc., great, e

Marty apres april 35 Marty 33 Marty 33

18. The method of claim 16 wherein said first nucleotide sequence comprises the nucleotide sequence encoding a full length RSV G protein shown in Figure 2 (SEQ ID NO:2).

- 19. The method of claim 15 wherein said first nucleotide sequence5 encodes a RSV G protein from which the transmembrane coding sequenceand sequences upstream thereto are absent.
 - 20. The method of claim 19 wherein said vector further comprises a neterologous signal peptide encoding nucleotide sequences immediately upstream of the 5'-terminus of said first nucleotide sequence.
- 10 21. The method of claim 20 wherein said signal peptide encoding sequence encodes the signal peptide for human tissue plasminogen activator.
 - 22. The method of claim 19 wherein said first nucleotide sequence comprises the nucleotide sequence shown in Figure 3 (SEQ ID NO:3).
- 15 23. The method of claim 19 wherein said first nucleotide sequence comprises a nucleotide sequence encoding a transverse RSV G protein shown in Figure 3 (SEQ ID NO:4).
 - 24. The method of claim 15 wherein said promoter sequence is an immediate early cytomegalovirus promoter.
- 20 25. The method of claim 15 wherein said second nucleotide sequence is the human cytomegalovirus Intron A.
 - 26. The method of claim 15 wherein the vector is a plasmid vector.
 - 27. The method of claim 26 wherein said plasmid vector is pXL5 as shown in Figure 4.
- 25 28. The method of dalm 25 wherein said vector is pXL6 as shown in Figure 5.
 - 29. The method of claim 15 wherein a balanced Th1/Th2 immune response is induced.
- 30. A method of using a gene encoding a respiratory syncytial virus 30 (RSV) G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein, to produce an immune response in a host, which comprises:

operatively linking said gene to at least one control sequence to produce a vector that will not replicate when introduced into the host to be protected, said control sequence directing expression of said RSV G protein 5 when introduced into a host to produce an immune response to said RSV G protein, and

introducing said vector into a host.

- The method of daim 30 wherein said gene encoding a RSV G protein 31. encodes a full length RSV G protein.
- The method of claim 30 wherein said gene encoding a RSV G protein 10 32. encodes a RSV G protein lacking the transmembrane domain and sequences upstream thereto.
- The method of claim 32 wherein said vector further comprises a 33. signal peptide encoding nucleotide sequences immediately upstream of the 15 5'-terminus of said first nucleotide sequence.
 - 34. The method of claim 33 wherein said signal peptide encoding sequence encodes the signal peptide for human tissue plasminogen activator.
- The method of claim 30 wherein said at least one control sequence 35. 20 comprises the immediate early cytomegalovirus promoter.
 - 36. The method of claim 35 including the step of:

operatively linking said gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection to said RSV G protein in said host.

- The method of claim 36 wherein said immunoprotection enhancing 25 37. sequence is introduced into said vector between said control sequence and said gene.
 - The method of claim 37 wherein said immunoprotection enhancing 38. sequence is the human cytomegalovirus Intron A.
- The method of claim 30 wherein said gene is contained within a 30 39. plasmid selected from the group consisting of pXL5 and pXL6.

40. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first nucleotide sequence encoding a RSV G protein or a SSV G protein fragment that generates antibodies that specifically react with RSV G protein,

operatively linking said first nucleotide sequence to at least one control sequence to produce a vector that will not replicate when introduced into the host to be protected, the control sequence directing expression of said RSV G protein when introduced to a host to produce an immune response to said RSV G protein,

operatively linking said first nucleotide sequence to a second nucleotide sequence to increase expression of said RSV G protein in vivo from the vector in the host, and

- formulating said vector as a vaccine for in vivo administration to a host.
 - 41. The method of claim 40 wherein said vector is selected from group consisting of pXL5 and pXL6.
 - 42. A vaccine produced by the method of claim 40.
- 20 43. A method of determining the presence of a respiratory syncytial virus (RSV) G protein in a sample, comprising the steps of:
 - (a) immunizing a host with a vector tht will not replicate when introduced into the host to be protected to produce antibodies specific for the RSV G protein, said vector comprising:
- a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein,
 - a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and
- 30 a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host,

15

- (b) isolating the RSV G protein specific antibodies;
- (c) contacting the sample with the isolated antibodies to produce complexes comprising any RSV G protein present in a sample and said isolated RSV G protein-specific antibodies; and
- 5 (d) determining the production of the complexes.
 - 44. The method of claim 43 wherein said vector is selected from the group consisting of pXL5 and pXL6.
 - 45. A diagnostic kit for detecting the presence of a respiratory syncytial virus (RSV) G protein in a sample, comprising:
- (a) a vector that will not replicate when introduced into the host to be protected capable of generating antibodies specific for the RSV G protein when administered to a host, the vector comprising:
 - a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein,
 - a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and
 - a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host;
 - (b) isolation means to isolate said RSV G protein-protein-specific antibodies;
- (c) contacting means to contact the isolated RSV G specific antibodies with the sample to produce a complex comprising any RSV G protein in the sample and RSV G protein specific antibodies, and
 - (d) identifying to determine production of the complex.
- 46. The diagnostic kit of claim 45 wherein said vector is selected from the 30 group consisting of pXL5 and pXL6.
 - 47. A method for producing antibodies specific for a G protein of respiratory syncytial virus (RSV) comprising:

4,544

SOP-27-99 15:31 From-SIM MCBURN

5

- (a) immunizing a host with an effective amount of a vector that will not replicate when instroduced into the host to be protected to produce RSV G-specific antibodies, said vector comprising:
- a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein.
- a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and
- a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host; and
 - (b) isolating the RSV G-specific antibodies from the host.
- 15 48. A method of producing monoclonal antibodies specific for a G protein of respiratory syncytial virus (RSV) comprising the steps of:
 - (a) constructing a vector that will not replicate when introduced into the host to be protected comprising:
 - a first nucleotide sequence encoding a RSV G protein or a RSV G protein fragment that generates antibodies that specifically react with RSV G protein,
 - a promoter sequence operatively coupled to said first nucleotide sequence for expression of said RSV G protein in the host, and
- a second nucleotide sequence located between said first nucleotide sequence and said promoter sequence to increase expression of said RSV G protein in vivo from said vector in the host;
 - (b) administering the vector to at least one mouse to produce at least one immunized mouse;
- 30 (c) removing B-lymphocytes from the at least one immunized mouse;

- (d) fusing the B- lymphocytes from the at least one immunized mouse with myeloma cells, thereby producing hybridomas;
- (e) cloning the hybridomas;
- 5 (f) selecting clones which produce anti-RSV G protein antibody;
 - (g) culturing the anti-RSV G protein antibody-producing clones; and then
 - (h) isolating anti-RSV G protein antibodies from the cultures.

09/462816 430 Rec'd PCT/PTO 14 JAN 2000

SEQUENCE LISTING

```
<110> LI, Xiaomao
      SAMBHARA, Suryaprakash
     KLEIN, Michel H.
<120> NUCLEIC ACID VACCINES ENCODING G PROTEIN OF RESPIRATORY
      SYNCYTIAL VIRUS
<130> 1038-1003 MIS:jb
<140>
<141>
<150> PCT/CA98/00697
<151> 1998-07-16
<150> 08/896,442
<151> 1997-07-18
<160> 8
<170> PatentIn Ver. 2.1
<210> 1
<211> 920
<212> DNA
<213> respiratory syncytial virus
<400> 1
tgcaaacatg tccaaaaaca aggaccaacg caccgctaag acactagaaa agacctggga 60
cactctcaat catttattat tcatatcatc gggcttatat aagttaaatc ttaaatctgt 120
agcacaaatc acattatcca ttctggcaat gataatctca acttcactta taattacagc 180
catcatattc atagcctcgg caaaccacaa agtcacacta acaactgcaa tcatacaaga 240
tgcaacaagc cagatcaaga acacaacccc aacatacctc actcaggatc ctcagcttgg 300
aatcagette tecaatetgt etgaaattae atcacaaace accaccatae tagetteaac 360
aacaccagga gtcaagtcaa acctgcaacc cacaacagtc aagactaaaa acacaacaac 420
aacccaaaca caacccagca agcccactac aaaacaacgc caaaacaaac caccaaacaa 480
acccaataat gattttcact tcgaagtgtt taactttgta ccctgcagca tatgcagcaa 540
caatccaacc tgctgggcta tctgcaaaag aataccaaac aaaaaaccag gaaagaaaac 600
caccaccaag cctacaaaaa aaccaacctt caagacaacc aaaaaagatc tcaaacctca 660
aaccactaaa ccaaaggaag tacccaccac caagcccaca gaagagccaa ccatcaacac 720
caccaaaaca aacatcacaa ctacactgct caccaacaac accacaggaa atccaaaact 780
cacaagtcaa atggaaacct tccactcaac ctcctccgaa ggcaatctaa gcccttctca 840
agtotocaca acatoogago accoatoaca accotoatot coacocaaca caacaogoca 900
gtagttatta aaaaaaaaaa
<210> 2
<211> 298
<212> PRT
<213> respiratory syncytial virus
<400> 2
Met Ser Lys Asn Lys Asp Gln Arg Thr Ala Lys Thr Leu Glu Lys Thr
                                      10
Trp Asp Thr Leu Asn His Leu Leu Phe Ile Ser Ser Gly Leu Tyr Lys
                                  25
             2.0
```

Leu Asn Leu Lys Ser Val Ala Gln Ile Thr Leu Ser Ile Leu Ala Met 35 40 45

Ile Ile Ser Thr Ser Leu Ile Ile Thr Ala Ile Ile Phe Ile Ala Ser 50 55 60

Ala Asn His Lys Val Thr Leu Thr Thr Ala Ile Ile Gln Asp Ala Thr 65 70 75 80

Ser Gln Ile Lys Asn Thr Thr Pro Thr Tyr Leu Thr Gln Asp Pro Gln 85 90 95

Leu Gly Ile Ser Phe Ser Asn Leu Ser Glu Ile Thr Ser Gln Thr Thr
100 105 110

Thr Ile Leu Ala Ser Thr Thr Pro Gly Val Lys Ser Asn Leu Gln Pro 115 120 125

Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Gln Thr Gln Pro Ser 130 135 140

Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn 145 150 155 160

Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys 165 170 175

Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys 180 185 190

Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr Phe 195 200 205

Lys Thr Thr Lys Lys Asp Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu 210 215 220

Val Pro Thr Thr Lys Pro Thr Glu Glu Pro Thr Ile Asn Thr Thr Lys 225 230 235 240

Thr Asn Ile Thr Thr Leu Leu Thr Asn Asn Thr Thr Gly Asn Pro 245 250 255

Lys Leu Thr Ser Gln Met Glu Thr Phe His Ser Thr Ser Ser Glu Gly 260 265 270

Asn Leu Ser Pro Ser Gln Val Ser Thr Thr Ser Glu His Pro Ser Gln 275 280 285

Pro Ser Ser Pro Pro Asn Thr Thr Arg Gln 290 295

<210> 3

<211> 715

<212> DNA

<213> respiratory syncytial virus

<400> 3

cacaaagtca cactaacaac tgcaatcata caagatgcaa caagccagat caagaacaca 60 accocaacat acctcactca ggatcctcag cttggaatca gcttctccaa tctgtctgaa 120 attacatcac aaaccaccac catactagct tcaacaacac caggagtcaa gtcaaacctg 180 caacccacaa cagtcaagac taaaaacaca acaacaaccc aaacacaacc cagcaagccc 240 actacaaaac aacgccaaaa caaaccacca aacaaaccca ataatgattt tcacttcgaa 300 gtgtttaact ttgtaccctg cagcatatgc agcaacaatc caacctgctg ggctatctgc 360 aaaagaatac caaacaaaaa accaggaaag aaaaccacca ccaagcctac aaaaaaacca 420 accttcaaga caaccaaaaa agatctcaaa cctcaaacca ctaaaccaaa ggaagtaccc 480 accaccaagc ccacagaaga gccaaccatc aacaccacca aaacaaacat cacaactaca 540 ctgctcacca acaacaccac aggaaatcca aaactcacaa gtcaaatgga aaccttccac 600 tcaacctcct ccgaaggcaa tctaagccct tctcaagtct ccacaacatc cgagcaccca 660 tcacaaccct catctccacc caacacaaca cgccagtagt tattaaaaaa aaaaa <210> 4 <211> 232 <212> PRT <213> respiratory syncytial virus <400> 4 His Lys Val Thr Leu Thr Thr Ala Ile Ile Gln Asp Ala Thr Ser Gln 5 Ile Lys Asn Thr Thr Pro Thr Tyr Leu Thr Gln Asp Pro Gln Leu Gly Ile Ser Phe Ser Asn Leu Ser Glu Ile Thr Ser Gln Thr Thr Ile Leu Ala Ser Thr Thr Pro Gly Val Lys Ser Asn Leu Gln Pro Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Gln Thr Gln Pro Ser Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn 105 Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro 120 Gly Lys Lys Thr Thr Lys Pro Thr Lys Lys Pro Thr Phe Lys Thr 135 Thr Lys Lys Asp Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu Val Pro 145 150 Thr Thr Lys Pro Thr Glu Glu Pro Thr Ile Asn Thr Thr Lys Thr Asn 170 165 Ile Thr Thr Leu Leu Thr Asn Asn Thr Thr Gly Asn Pro Lys Leu

185

205

Thr Ser Gln Met Glu Thr Phe His Ser Thr Ser Ser Glu Gly Asn Leu

200

180

```
Ser Pro Ser Gln Val Ser Thr Thr Ser Glu His Pro Ser Gln Pro Ser
                       215
   210
Ser Pro Pro Asn Thr Thr Arg Gln
225
                   230
<210> 5
<211> 4912
<212> DNA
<213> respiratory syncytial virus
<400> 5
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 60
cagettgtet gtaageggat geegggagea gacaageeeg teagggegeg teagegggtg 120
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 180
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcagattgg 240
ctattggcca ttgcatacgt tgtatccata tcataatatg tacatttata ttggctcatg 300
tccaacatta ccgccatgtt gacattgatt attgactagt tattaatagt aatcaattac 360
ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg 420
cccgcctggc tgaccgccca acgacccccg cccattgacg tcaataatga cgtatgttcc 480
catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac 540
tgcccacttg gcagtacatc aagtgtatca tatgccaagt acgccccta ttgacgtcaa 600
tgacggtaaa tggcccgcct ggcattatgc ccagtacatg accttatggg actttcctac 660
ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta 720
catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc accccattga 780
cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtaacaa 840
ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg tgggaggtct atataagcag 900
agetegttta gtgaacegte agategeetg gagaegeeat ceaegetgtt ttgaeeteea 960
tagaagacac cgggaccgat ccagcctccg cggccgggaa cggtgcattg gaacgcggat 1020
tccccgtgcc aagagtgacg taagtaccgc ctatagactc tataggcaca cccctttggc 1080
tettatgeat getataetgt ttttggettg gggeetatae acceeegett cettatgeta 1140
taggtgatgg tatagettag cetataggtg tgggttattg accattattg accactecce 1200
tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca caactatctc 1260
tattggctat atgccaatac tctgtccttc agagactgac acggactctg tatttttaca 1320
ggatggggtc ccatttatta tttacaaatt cacatataca acaacgccgt cccccgtgcc 1380
cgcagttttt attaaacata gcgtgggatc tccacgcgaa tctcgggtac gtgttccgga 1440
catgggctct tctccggtag cggcggagct tccacatccg agccctggtc ccatgcctcc 1500
agcggctcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag acttaggcac 1560
agcacaatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg gtatgtgtct 1620
gaaaatgagc gtggagattg ggctcgcacg gctgacgcag atggaagact taaggcagcg 1680
gcagaagaag atgcaggcag ctgagttgtt gtattctgat aagagtcaga ggtaactccc 1740
gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt tgctgccgcg 1800
cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat gggtcttttc 1860
tgcagtcacc gtcgtcgaca cgtgtgatca gatatcgcgg ccgctctaga ccaggcgcct 1920
ggatccagat ctgctgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgtg 1980
ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt 2040
aagggggagg attgggaaga caatagcagg catgctgggg atgcggtggg ctctatgggt 2160
acccaggtgc tgaagaattg acccggttcc tcctgggcca gaaagaagca ggcacatccc 2220
cttctctgtg acacaccctg tccacgcccc tggttcttag ttccagcccc actcatagga 2280
cactcatagc tcaggagggc tccgccttca atcccacccg ctaaagtact tggagcggtc 2340
tctccctccc tcatcagccc accaaaccaa acctagcctc caagagtggg aagaaattaa 2400
agcaagatag gctattaagt gcagagggag agaaaatgcc tccaacatgt gaggaagtaa 2460
tgagagaaat catagaattt cttccgcttc ctcgctcact gactcgctgc gctcggtcgt 2520
tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc 2580
aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa 2640
aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa 2700
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 2760
```

```
ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc 2820
cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag 2880
ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga 2940
ccqctqcqcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc 3000
gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac 3060
agagttcttg aagtggtggc ctaactacgg ctacactaga agaacagtat ttggtatctg 3120
cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca 3180
aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa 3240
aggateteaa gaagateett tgatetttte taeggggtet gaegeteagt ggaacgaaaa 3300
ctgacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt 3360
aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt ggtctgacag 3420
ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat 3480
agttgcctga ctcggggggg gggggcgctg aggtctgcct cgtgaagaag gtgttgctga 3540
ctcataccag gcctgaatcg ccccatcatc cagccagaaa gtgagggagc cacggttgat 3600
gagagetttg ttgtaggtgg accagttggt gattttgaac ttttgetttg ccaeggaacg 3660
gtctgcgttg tcgggaagat gcgtgatctg atccttcaac tcagcaaaag ttcgatttat 3720
tcaacaaagc cgccgtcccg tcaagtcagc gtaatgctct gccagtgtta caaccaatta 3780
accaattgtg attagaaaaa ctcatcgagc atcaaatgaa actgcaattt attcatatca 3840
ggattatcaa taccatattt ttgaaaaagc cgtttctgta atgaaggaga aaactcaccg 3900
aggcagttcc ataggatggc aatatcctgg tatcggtctg cgattccgac tcgtccaaca 3960
tcaatacaac ctattaattt cccctcgtca aaaataaggt tatcaagtga gaaatcacca 4020
tgagtgacga ctgaatccgg tgagaatggc aaaagcttat gcatttcttt ccagacttgt 4080
tcaacaggcc agccattacg ctcgtcatca aaatcactcg catcaaccaa accgttattc 4140
attcgtgatt gcgcctgagc gagacgaaat acgcgatcgc tgttaaaagg acaattacaa 4200
acaggaatcg aatgcaaccg gcgcaggaac actgccagcg catcaacaat attttcacct 4260
gaatcaggat attettetaa taeetggaat getgttttee eggggatege agtggtgagt 4320
aaccatgcat catcaggagt acggataaaa tgcttgatgg tcggaagagg cataaattcc 4380
gtcagccagt ttagtctgac catctcatct gtaacatcat tggcaacgct acctttgcca 4440
tgtttcagaa acaactctgg cgcatcgggc ttcccataca atcgatagat tgtcgcacct 4500
gattgcccga cattatcgcg agcccattta tacccatata aatcagcatc catgttggaa 4560
tttaatcgcg gcctcgagca agacgtttcc cgttgaatat ggctcataac gttccttgta 4620
ttactgttta tgtaagcaga cagttttatt gttcatgatg atatattttt atcttgtgca 4680
atgtaacatc agagattttg agacacaacg tggctttccc cccccccca ttattgaagc 4740
atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa 4800
caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt 4860
attatcatga cattaaccta taaaaatagg cgtatcacga ggccctttcg tc
                                                                   4912
<210> 6
<211> 188
<212> DNA
<213> respiratory syncytial virus
<400> 6
ctgcagtcac cgtcgtcgac cagagctgag atcctacagg agtccagggc tggagagaaa 60
acctctgcga ggaaagggaa ggagcaagcc gtgaatttaa gggacgctgt gaagcaatca 120
tggatgcaat gaagagagg ctctgctgtg tgctgctgct gtgtggagca gtcttcgttt 180
                                                                   188
cgcccagc
<210> 7
<211> 11
 <212> DNA
<213> respiratory syncytial virus
 <400> 7
gatccactca g
```

<210> 8
<211> 11
<212> DNA
<213> respiratory syncytial virus
<400> 8
gtgagtccta g

1/19

Restriction Map of the RSV G Gene




FIG.24

	2/19								
55	109	163	217	271	325				
Gaa aag acc	AAG TTPA AAT	AIC ICA ACT	AAA GTC ACA	ACA ACC CCA	CTG TCT GAA				
Glu Lys Thr	Lys Leu Asn	Ile Ser Ihr	Lys Val Thr	Thr Thr Pro	Leu Ser Glu				
46 AAG ACA CTA Lys Thr Leu	GGC TTA TAT Gly Leu Tyr	154 GCA ATG ATA Ala Met 11e	208 GCA AAC CAC Ala Asn His	262 ATC AAG AAC Ile Lys Asn '	316 TTC TCC AAT (Phe Ser Asn)				
37	91	145	199	253	307				
CGC ACC GCT	ATA TCA TCG	TCC AITT CTG	ATA GCC TCG (ACA AGC CAG	GGA ATC AGC				
Arg Thr Ala	Ile Ser Ser	Ser Ile Leu	Ile Ala Ser	Thr Ser Gln	Gly 11e Ser				
28 AAG GAC CAA Lys Asp Gln	82 TIA TIA TIC Leu Leu Phe	136 ATC ACA TTA Ile Thr Leu	ATC ATA TTC. Ile Ile Phe	244 CAA GAT GCA Gln Asp Ala	298 CCT CAG CTT Pro Gln Leu				
19	73	127	172 181	226 235	289				
TCC AAA AAC	CTC AAT CAT	CAA	ATA ATT ACA GCC 1	ACT GCA ATC ATA (CT CAG GAT				
Ser Lys Asn	Leu Asn His	Gln	11e 11e Thr Ala	Thr Ala Ile Ile (hr Gln Asp				
10	64	118	172	226	280				
TGCAAAC ATG	TCG CAC ACT	CTT AAA TCT GTA GCA	TCA CTT ATA	CTA ACA ACT	ACA TAC CTC A				
Met	Trp Asp Thr]	Leu Lys Ser Val Ala	Ser Leu Ile	Leu Thr Thr	Thr Tyr Leu T				

FIG 2B

The state of the s

The state of the s

379 TCA Ser AAG Lys GIC Val GGA GLYPro 8 ACA Thr Thr 361 ACA TCA Ser GCI Ala Leu 352 CTA Ile ATA ACC Thr 343 ACC Thr ACC Thr Gln CAA 334 TCA Set

CAA Gh ACA Thr CAA Gln ACC Thr 424 ACA Thr ACA Thr ACA Thr AAC Asn AAA Liys ACT Thr 406 AAG Liys GIC Val ACA Thr 397 ACA Thr Pro 8 Gln 388 CAA CIG Leu Asn

Asn 487 AAT Pro Lys AAA 478 AAC Asn Pro 8 Pro 8 469 AAA Lys AAC Gln Asn CAA 460 CGC Arg CAA Gln Lys AAA 451 ACA Thr ACT Thr Pro 8 442 AAG Liys Ser Pro

3/19

541 AAC Asn Ser AGC 1300 C_{YS} 532 AIPA Ile AGC Ser 130 Cys523 ccc Pro Val GIIA TIT Phe 514 AAC Asn TILL Phe GIG Val Glu 505 GAA TIC GAC His Phe 496 TTT GAT ASp Asn

€ GLY Pro 8 AAA Lys 286 AAA Lys AAC Asn 577 CCA Pro ATA IleAGA Arg AAA Lys 268 333 CysAIC Ile GCT 559 133 Trp IGC Cys ACC Thr 550 Pro Asn

595 AAG Liys

649 GAT Asp ĽSS AAA Liys AAA 640 ACC 먑 AAG Lys 631 TTC Phe ACC Thr Pro 8 Lys 622 AAA AAA [5] ACA Thr 613 CCT Pro AAG Liys ACC Thr ACC 604 Thr

FIG. 20

			4/19		
	OCC ACA GAA Pro Ihr Glu	757 CTC ACC AAC Leu Thr Asn	811 CAC TCA ACC His Ser Thr	865 GAG CAC CCA Glu His Pro	AAAAAA
694	ACC ACC AAG CY Thr Thr Lys P	748 ACT ACA CTG C Thr Thr Leu L	802 GAA ACC TTC C Glu Thr Phe H	856 ACA ACA TCC G I'hr I'hr Ser G	914 TAGITATTAA AAAAAAAA
685	GAA GTA CCC A	739 AAC ATC ACA ASN Ile Thr	793 AGT CAA ATG (Ser Gln Met (847 CAA GTC TCC / Gln Val Ser [901 ACA CGC CAG Thr Arg Gln
9/9	AAA CCA AAG Lys Pro Lys	730 ACC AAA ACA . Thr Lys Thr .	784 AAA CTC ACA Lys Leu Thr	838 AGC CCT TCT (Ser Pro Ser (892 CCC AAC ACA . Pro Asn Thr '
	CAA ACC ACT Gln Thr Thr	721 ATC AAC ACC Ile Asn Thr	775 AAT CCA Asn Pro	829 GGC AAT CTA Gly Asn Leu	883 TCA TCT CCA Ser Ser Pro
658	CTC AAA CCT Leu Lys Pro	712 GAG CCA ACC Glu Pro Thr	766 AAC ACC ACA GGA ASN Thr Thr Gly	820 TCC TCC GAA GGC Ser Ser Glu Gly	874 TCA CAA CCC Ser Gln Pro

FIG.34

FIG.3B

			6/19	
486 162	540 180	594 198	648 216	699
ACC AAA AAA GAT CTC AAA CCT CAA ACC ACT AAA CCA AAG GAA GTA CCC ACC ACC ACC ACC Thr Lys Lys Lys Asp Leu Lys Pro Gln Thr Thr Lys Pro Lys Glu Val Pro Thr Thr	AAG CCC ACA GAA GAG CCA ACC ATC AAC ACC ACC AAA ACA AAC ATC ACA ACT ACA LLYS Pro Thr Glu Glu Pro Thr Ile Asn Thr Thr Llys Thr Asn Ile Thr Thr Thr	CTG CTC ACC AAC ACC ACA GGA AAT CCA AAA CTC ACA AGT CAA ATG GAA ACC Leu Leu Thr Asn Asn Thr Thr Gly Asn Pro Lys Leu Thr Ser Gln Met Glu Thr	TTC CAC TCA ACC TCC TCC GAA GCC AAT CTA AGC CCT TCT CAA GTC TCC ACA ACA ACA ACA AGC Ser Thr Ser Ser Glu Gly Asn Leu Ser Pro Ser Gln Val Ser Thr Thr 1.	TOC GAG CAC CCA TOA CAA COC TOA TOT COA COC AAC ACA ACA CGC CAG TAG Ser Glu His Pro Ser Gln Pro Ser Ser Pro Pro Asn Thr Ara Gln .

TTATTAA AAAAAAA



7/19




FIG.4.




FIG.6A

			9/19				
70	140	210	280	350	420	490	560
CAGCITIGICI	TCGGGGCTGG	CCGCACAGAI	TCATAATATG	TAITTAATAGT	CGGIAAAIGG	CATAGTAACG	GCAGIACAIC
60	130 140	200	270	340	410	480	550
GAGACCIGICA	TTGCCGGGTG TCGCGCCTGG	GIGIGAAAIA	TGFATCCAFA	AITGACIAGI	ACATTAACTTTA	CGINIGITICC	TGCCCACTTG
10 20 30 40 50 60 70 TOGOGOGITIT COGTGATAAC TOTGACACAT GCAGOTCOOG GAGACGGTCA CAGOTTGIOT	110 120 TCAGGGGGG TCAGCGGGIG	180 190 CIGAGAGIGC ACCATATGCG	250 260 270 280 CIATTGGCCA TIGCATACGT TGTATCCATA TCATAATATG	290 340 350 TACAITITATA TIGGCICATG TCCAACAITA CCGCCAIGIT GACAITIGAIT AITIGACTAGI TAITIAATAGI	360 370 380 390 400 410 420 AAIICAAITIAC GGGGICAITIA GITICAIIAGCC CATAIIAIGGA GITICCGCGITI ACAIIAACITIA CGGIAAATIGG	460 470 480 490 cocatitgacg icaalaatga ceiaatitaacg	530 540 550 GIGGAGIAIT TACGGIAAAC TGCCCACITG
40	110	180	250	320	390		530
TCTGACACAT	TCAGGGCGCG	CTGAGAGIGC	CTATTGGCCA	CCGCCAIGIT	CATATATGGA		GIGGAGIAIT
30	100	170	240	310	380	450	520
GGTGAAAACC	GACAAGCCCG	GCAGAITIGIA	AICAGAITIGG	TCCAACAITIA	GTTCATAGCC	ACCACCCCCG	ACCICAAIGG
20	80 90 100	150 160 170	220 230	300	370	430 440 450 cccccigacidas Igaccoccca accaccidas	500 510
CGGICAIGAC	GIRAGCOGAI GCCGGGAGCA GACAAGCCCG	CITYAACIYATG CGGCAICAGA GCAGAITGTA	3CGTPAGGAG AAAATACCGC ATCA	TIGGCICAIG	GGGGICAITIA		CCAATAGGGA CTITICCAITIG
10	80	150	220	290	360	430	500
TCGCGCGITIT	GTPAGCGGAT	CITPACIPATG	GOGIFAAGGAG	TACAITITAITA	AAITCAAITIAC	CCCGCCTGGC	CCAATAGGGA

	Y	ב
C	(Ō
_		
	1)
_	1	-
L	1	_

		10 / 19	ı			
700	770	840	910	980	1050	1120
TATTACCATG	CCAAGICICC	GICGIAACAA	AGCICGITIA	CGGGACCGAT	TAAGTACCGC	GGCCTATAC
690	760	830	900	970	1040	1080 1090 1100 1110 1120 CCCCTTIGC TCTTAIGCTIG GGCCTATAC
TAGICATOGO	ACGGGGGAITIT	TITICCAAAAT	ATATAAGCAG	Tagaagacac	AAGAGIGACG	
680	750	820	890	960	1030	1100
AICTACGTAT	GGITTIGACTC	TCAACGGGAC	TGGGAGGICT	TTGACCTCCA	TCCCGIGCC	GCIMIACIGI
670 TTGGCAGTAC			880 GCGTGTACGG	950 CCACGCIGIT	1020 GAACGCGGAT	1090 TCTTAIGCAT
	730	800	870	940	1010	1080
	CATCAATGGG	AGITITGITIT	TGGGCGGTAG	GAGACGCCAT	CGGIGCAITG	CCCCTTTGGC
650	720	790	860	930	1000	1060 1070
ACCTIVATGGG	TTTGGCAGTA	CGTCAATGGG	TTGACGCAAA	AGAICGCCIG	CGGCCGGGAA	CTATAGACTC TATAGGCACA
640	710	780	850	920	990	1060
CCAGTACATG	GICAIGCGGI	ACCCCATTGA	CICCGCCCA	GIGAACCGIC	CCAGCCTCCG	CTATAGACTC
	660 670 680 690 ACTITICCTAC TIGGCAGTAC ATCITACGIAT TAGICATCGC TATTACC	ACTITICCTAC TTGGCAGTAC ATCTACGTAT 730 740 750 CATCAATGGG CGTGGATAGC GGTTTGACTC	670 680 690 700 TTGGCAGTAC TAGTICATCGC TATTTACCATG 740 750 760 770 CGTGGATAGC GGTTTGACTC ACGGGGATTT CCAAGTCTCC 810 820 840 GGCACCAAAA TCAACGGGAC TTTCCAAAAT GTCGTAACAA	670 680 CAGTAC ATCTACGTAT 740 750 GATAGC GGTTTGACTC 810 820 CCAAAA TCAACGGGAC 880 890 GTACGG TGGGAGGTCT	670 680 700 CAGITAC TAGICAICG TATTACCAIG 740 750 760 770 GAITAGCIC ACGGGGATTT CCAAGICICC 810 820 840 CCAAAA TCAACGGGAC TITICCAAAAT GICGIPAACAA 880 890 900 910 3TACGG TOGGAGGICT ATAITAAGCAG AGCTCGITTAA 950 960 970 980 3CIGITT TIGACCICCA TAGAAGACAC 980 3CIGITT TIGACCICCA TAGAAGACAC CGGGGACCGATT	670 680 690 700 CCAGITAC TAGICAICOS TATITACCAIG 740 750 760 770 GAITAGC ACGGGGAITT CCAAGICTCC 810 820 830 840 CCAAAA TCAACGGGAC TITCCAAAA GICGITAACAA 880 890 900 910 GIRACAA ATATAAAGACAC AGCICGITTAA 950 960 970 980 GCIGIT ATAGAAGACAC CGGGAACCCATTAA 1020 1030 1040 1050 GCGGAT TTCCCCGIGCC AAGAGICACG TTAAGIAACCCCCATTAA

,	(
	Č	Č
	(Г
	<u>-</u>	•

Arter from the form the first first first of the first first form and the first firs

		11/19				
1260	1330	1400	1470	1540	1610	1680
CAACTATETE	GGATGGGGTC	AITPAACATA	CGGCGGAGCT	CICCTAACAG	TGGCGGTAGG	TAAGGCAGCG
	1320 TAITTTTACA	1390 CGCAGITITI	1460 TCTCCGGTAG		1600 CACAAGGCCG	1650 1660 1670 1680 1670 1680 GCTCGCCGCAG ATGGAAGACT TAAGGCAGG
1240	1310	1380	1450	1520	1590	1660
CATAACATGG	ACGGACTCTG	CCCCCFIGCC	CATGGGCTCT	GGICGCICGG	CAGIGIGCCG	GCTGACGCAG
1230	1300	1370	1440	1510	1580	1650
ATTACTAATC	AGAGACTGAC	ACAACGCCGT	GIGITCCGGA	AGCGGCTCAT	CCACCACCAC	GGCTCGCACG
1220	1290	1360	1430	1500	1570	1640
GATACTITTCC	TCIGICCTIC	CACATATACA	TCTCGGGTAC	CCATGCCTCC	AGCACAATGC	GIGGAGAITG
1210	1280	1350	1420	1490	1560	1620 1630 1640
TAITIGGIGAC	ATGCCAATAC	TITPACAAATT	TCCACGCGAA	AGCCTGGIC	ACTTAGGCAC	GIATGIGICT GAAATGAGC GIGGAGAITG
1200	1270	1340	1410	1480	1550	1620
ACCACTCCCC	TATTGGCTAT	CCATITIALTA	GCCIGGGAIC	TCCACATCCG	TGGAGGCCAG	GINIGIGICT
	1210 1220 1230 1240 1250 TAITIGGIGAC GATACTITICC ATTACTIAATC CATAACATGG CTCTTTIGCCA CAACTA	GATACTITICC ATTACTAATC CATAACATGG CTCTTTGCCA CAACTA 1290 1300 1310 1320 TCTGTCCTTC AGAGACTGAC ACGGACTCTG TAITTTTACA GGATGG				·

PCT/CA98/00697

_	_
	m
ч	

-1G.6D

			12 / 19				
1750	1820	1890		2030	2100	2170	2240
GIIGCGGIGC	GACATTAATAG	CGIGIGAICA		CCTAATAAAA	GCAGGACAGC	CICIMIGGI ACCCAGGIGC	ACACACCCTG
1720 1730 1740 1750 GIAITCICAT AAGAGICAGA GGIAACICCC GIIGCGGIGC	1810 1820 CGCGCCACCA GACATAATAG	1850 1860 1870 1880 1890 ICCITICCAT GGSICTITIC IGCAGICACC GICGICGACA CGIGIGAICA	1920 1930 1940 1950 1960 CCAGGCGCCT GGATCCAGAT CTGCTGTGCC TTCTAGTTGC CAGCCATCTG	2010 2020 TOCCACTCCC ACTGTCCTTT	2090 GIGGGGIGGG	_	2200 2210 2220 2230 2240 ICCIGGGCCA GAAAGAAGA GGCACAICCC CIICICIGIG ACACACCCIG
1730	1790 1800	1870	1940	2010	2070 2080	2130 2140 2150 CARROCAGE CARROCAGE CARROCAGE CARROCAGE CARROCAGE ARGCOGIGGE	2220
AAGAGICAGA	CAGIRCICGI IGCIGCCGCG	TGCAGICACC	CIGCIGIGCC	TECCACTCCC	GIGICATICI AITICIGGGGS		GGCACATCCC
1720		1860	1930	1990 2000	2070	2140	2210
GIAITICICAI		GGGICITITIC	GGATCCAGAT	CCITCCITGA CCCIGGAAGG	GIGICAITCI	CATGCTGGGG	GAAAGAAGCA
1710	1780	1850	1920	1990	2060	2130	2200
CIGAGITGIT	GIAGICIGAG	TCCITTCCAT	CCAGGCGCCT	CCTTCCTTGA	GICIGAGIAG	CAAITAGCAGG	TCCTGGGCCA
1700	1770	1840	1910	1980	2050	2120	2190
AIGCAGGCAG	GGAGGGCAGI	AACAGACTGT	CCGCTCTAGA	CICCCCGIG	GCAICGCAIT	ATTGGGAAGA	ACCCGGTTCC
1690 1700	1760 1770	1830 1840	1900 1910	1970 1980	2040 2050	2110 2120	2180 2190
GCAGAAGAAG ATGCAGGCAG	IGITPAACGGT GGAGGGCAGT	CIGACAGACT AACAGACIGI	GATATCGCGG CCGCTCTAGA	TIGITIGCCC CICCCCGIG	IGAGGAAAIT GCAICGCAIT	AAGGGGGAGG ATTGGGAAGA	TGAAGAATTG ACCCGGTTCC

0

PCT/CA98/00697

FIG.6E

		1.	2 / 10				
2310 TCCCCTTCA	2380 ACCTAGCCTC		2520 <u>25</u> GCTCGGTCGT	2580 2590 CCACAGAATC AGGGGATAAC	2660 TTGCTGGCGT	2730 GGCGAAACCC	2800 TCCGACCCTG
2300 TCAGGAGGGC	2370 ACCAAACCAA	2440 AGAAAAIGCC	2510 GACTCGCTGC		2650 AAAGGCCGCG	2720 AGTCAGAGGT	2790 GCICICCIGI
2290 CACTCATAGE	2360 2370 2380 TCATCAGCCC ACCAAACCAA ACCTAGCCTC	2430 2440 2450 GCAGAGAGAG AGAAAATGCC TCCAACATGT	2500 CICGCICACT	2570 ATACGGTTAT	2640 GGAACCGIAA	2710 TCGACGCTCA	2780 TCCCTCGIGC
2280 2290 2300 ACTICATAGGA CACTICATAGGA CACTICATAGGA CACTICATAGG TICAGGAGGGC	2350 TCTCCCTCCC	2420 GCTAITTAAGT	2490 2500 2510 crrcccrrc cacrcccrcc	2550 2560 2570 CAGCICACIC AAAGGCGGIA AIACGGIIIAI	2620 2630 2640 2650 AAAAAGGCCAG CAAAAGGCCCAG CAAAAGGCCCA GGAACCGTAA AAAGGCCGCG	2690 2700 2710 2720 ccreaceage arcaeager	2760 2770 AGGCGITITCC CCCIGGAAGC
2270 TITCCAGCCCC	2340 TOGAGOGGIC		2480 CATAGAATTT				2760 AGGCGITITCC
2250 2260 TCCACGCCC TGGITCITAG	2320 2330 ATCCCACCG CTAAAGTACT	2410 CAAGAGIGGG AAGAAATTAA AGCAAGATAG	2460 2470 GAGGAAGTAA TGAGAGAAAT	2530 2540 TCGGCTGCGG CCAGCGGTAT	2600 2610 3CAGGAAAGA ACATGTGAGC	2670 2680 TITTICCATAG GCTCCGCCC	2740 2750 GACAGGACTA TAAAGATACC
2250 TCCACGCCCC	2320 ATCCCACCCG	2390 CAAGAGIGGG	2460 GAGGAAGIAA	2530 TCGGCTGCGG	2600 GCAGGAAAGA	2670 TITICCATAG	2740 GACAGGACIFA

ŝ	75	3
-	:	ą
٠.	ř	ij
-	:	4
	÷	÷
122	Ė	Ģ
ã	:	٩
÷	5	1
Healt Life II Healt House Chall .	227113	3
	•	3
3	ä	3
=	•	×
100	:	
Head?	ŧ	ą
Ĕ,	5	
Ξ		
.=	=	:
1	×	5
	-	3
	Ξ	2
	ï	7
ŝ	*	٩
:	:	=
ä	=	ą
4	:	
thirth it that made that the	2	E
Ĕ,		
	-	•
-		-

FG.6

O 4'	0 4	0 4	14/19	0.4	O (T)	C	C EI
2870	2940	3010	3080 7-	3150	3220	3290	3360
TCACGCTGTA	TTCAGCCCGA	GCCACTGGCA	AAGTOGTOGC 6	CCTTCGGAAA	TTGCAAGCAG	GACCCICAGI	AGAICCITIT
2840 2850 2860 CCTTCGGGAA GCGTGGCGCT TTCTCATAGC	2930	3000	3070	3140	3210	3280	3350
	GAACCCCCCC	ACGACITIAIC	AGAGITCITG	AAGCCAGITA	GITITITIGE	TACCGCCTCT	ATCTTCACCT
2850	2920	2990	3060	3130	3200	3270	3340
GCTIGGCGCT	CIGIGIGCAC GAA	CCGGTAAGAC	GCGCIGCIAC	CECTICIECTE	GGIAGCGGIG	IGAICITITIC	ATCAAAAAGG
	2910 CCAAGCTGGG	2980 TGAGICCAAC	3050 AGGIMIGING	3120 TIGGIAICIG	3180 3190 CCGGCAAACA AACCACCGCT	3250 3260 AGGAICICAA GAAGAICCIT	3330 ICAICACAIT
2830 CGCCITICIC	2900 GICGITCGCT	2950 2960 2970 2980 2990 3000 3010 COCTOCOCC TTATCOGGTA ACTATCGTCT TGAGTCCAAC CCOGTAAGAC ACGACTTATC GCCACTGGCA	3020 3030 3040 3050 3060 3070 3080 acagecractic giraccacactic acagecractic giraccacactic acagetic acag	3110 AGAACAGIAT	3180 CCGGCAAACA	3250 AGGAICICAA	3300 3350 3360 3360 3360 3340 3350 3360 3360 3360 3360 3360
2810 2820 CCGCTTACCG GATACCTGTC	2890 2890	2960	3030	3090 3100	3160 3170	3230 3240	3310
	GGIAICICAG TICGGIGIAG	TTATCCOGTA	GTAACAGGAT	CTAACTACGG CTACACTAGA	AAGAGIIGGI AGCICIIGAI	CAGATTACGC GCAGAAAAA	CTGACGITAA
2810	2880	2950	3020	3090	3160	3230	3300
CCGCTTACCG	GGIMICICAG	CCGCIGCGCC	GCAGCCACTG	CTPACTPACGG	AAGAGITGGI	CAGAITIACGC	GCAACCAAAA

FIG 60

			15/19				
3430	3500	3570	3640	3710	3780	3850	3920
TTACCAATGC	CICGGGGGGG	CCCCATCATC	GATTTTGAAC	TCAGCAAAAG	CAACCAATTA	GGAITIAICAA	ATAGGATGGC
3420	3490	3560	3620 3630	3700	3770	3840	3910
Geichgacag	AGIIGCCIGA	GCCTGAATCG	TTGTAGGTGG ACCAGTTGGT	AICCITCAAC	GCCAGIGITA	AITCAIAICA	AGGCAGITCC
3410 GAGTAAACTT	3480 GITCAICCAT	3530 3540 3550 3560 COTCAPACCAG GCCTGAATCG	3620 TTGTAGGTGG	3690 GCGICAICIG	3760 GIAATGCTCT	3810 3820 3830 3840 3850 CICAICGAGC AICAAAIGAA ACIGCAAITIT AITICAIAICA GGAITAICAA	3920 3910 3920 3900 3910 3920 CGITICIGIA AIGAAGGACA AAACICACCG AGGCAGITCC AIAGGAIGGC
3390 3400	3470	3540	3610	3680	3750	3820	3890
AATCAATCTA AAGTATATAT	TGICTATITIC	GIGITIGCIGA	GAGAGCTTTG	TCGGGAAGAT	TCAAGICAGC	ATCAAATGAA	ATGAAGGAGA
	3460	3530	3600	3670	3740	3810	3880
	CICAGCGAIC	CGTGAAGAAG	CACGGIIIGAI	GICIGCGITG	CGCCGICCCG	CICAICGAGC	CGITICIGIA
3370 3380	3440 3450	3510 3520	3590	3650 3660	3730	3790 3800	3860 3870
AAATTAAAAA TGAAGITITIA	TTAATCAGTG AGGCACCTAT	GGGGCGCTG AGGTCTGCCT	GTGAGGGAGC	TITITIGCTITIG CCACGGAACG	TCAACAAAGC	ACCAAITGIG AITIAGAAAA	TACCATATTT TTGAAAAGC
3370	3440	3510	3580 3590	3650	3720	3790	3860
AAATTTAAAA	TTAATCAGIG	GGGGGCCTG	CAGCCAGAAA GIGAGGGAGC	TITIGCITIG	TICGAITITAI ICAACAAAGC	ACCAAITIGIG	TACCATATTT

	;	:
=	::	2
	i	7
-	=	4
	F	٦
37	÷	Ą
Track March	Janat.	٦
Rem Sudi		2
2	:	:
ů,	3	4
and the	;	111
Heady	in the same	20
Harry HE	150152.	2000
Harry HE	150152.	::
Harry HE	150152.	2000
Here I	150152.	::

FIG.6F

			16/19				
3990	4060	4130	4190 4200 년	4270	4340	4410	4480
CCCCTCGTCA	AAAAGCITAT	CATCAACCAA	TGITAAAAGG ACAAITIACAA ^년	GAATCAGGAT	CATCAGGAGT	CAICICAICI	TTCCCATACA
3980 CTATTAATTT	4050 4060 TCACAATCCC AAAAGCTTAT	4090 4100 4110 4120 4130 4130 TCAACAGGCC AGCCATTACG CTCGTCATCA AAAICACTCG CATCAACCAA		4260 ATTTTCACCT	4330 AACCATGCAT	4380 4390 4400 4410 catraaatiicc gicagccagi tiagicigac caicicaica	4420 4430 4440 4450 4460 4470 4480 GIBACAICAT TOGCAACOCT ACCTITIOCCA TGITITCAGAA ACAACTCTOG CGCATCOGGC TTCCCATACA
3960 3970	4040	4110	4170 4180	4250	4320	4390	4460
TCGICCAACA TCAAIACAAC	CTGAATCCGG	CICGICAICA	GAGACGAAAT ACGCGATCGC	CATCAACAAT	AGIGGICAGI	GICAGCCAGI	ACAACTCTGG
3960	4030	4100	4170	4240	4310	4380	4450
TCGTCCAACA	TCAGTGACGA	AGCCAITIACG	GAGACGAAAI	GCGCAGGAAC ACTGCCAGCG	CGGGGAICGC	CATAAATTCC	IGITICAGAA
3950	4020	4090	4160	4230	4300	4370	4440
CGAITICCGAC	GAAATCACCA	TCAACAGGCC	GCGCCTGAGC	GCGCAGGAAC	GCIGITITICC	TCGCAAGAGG	ACCTITIGCCA
3930 3940	4030 4030 4030 4020 4030 4030 4030 4030	4070 4080	4140 4150	4210 4220	4280 4290 4300	4350 4360 4370	4430
AATATCCTGG TATCGGTCTG		GCATTICITT CCAGACIIGE	ACCGITAITC AITCGIGAIT	ACAGGAATCG AATGCAACCG	AITCITCIPA TACCIGGAAL GCIGITITCC	ACCCATAAAA TCCTTCATCG TCCCAACACG	TGGCAACGCT
3930	4000	4070	4140	4210	4280	4350	4420
AATATCCTGG	AAAATAAGGT	GCATTICITT	ACCGITAITC	ACAGGAATCG	AITCITCIAA	accentara	GIYACAICAI

4900

4890

4880

4870

4850

4840

AAAGIIGOCAC CIIGAGGIICIA AGAAACCAITI AITIAIICAIGA CAITIAACCIA TAAAAAITAGG CGIAICACGA

FIG.6

		17	7/19	
4550	4620	4690	4760 5	4830
AATCAGCATC	GITCCITGIA	AIGIAACAIC	GTTATTGTCT	AITICCCCGA
4510 4520 4530 4540 4550 GAITIGCCCGA CAITFAITCCC ACCCATTIFA TACCCATFATA AATCAGCAITC	4580 4590 4600 4610 4620 GCCICCAGCA ACACGITICC CGITICAATAT GGCICATAAC GITICCITIGIA	4650 4660 4670 4680 4690 AGTITITIATITI GITICALGATG ATATATITITIT ATCITIGIGCA AIGTAACATC	4720 4730 4740 4750 4760 IGOCTITICCC CCCCCCCCA TIMITICAAGC AITITAICAGG GITAITIGICT	4790 4800 4810 4820 4830 4830 4830 4830
4530	4600	4670	4740	4810
ACCCATITIA	CGITCAAIAI	ATATATTITT	TIPATTGAAGC	CRAATAGGGG
4520	4590	4660	4730	4800
CAITAICGCG	AGACGITICC	GITCAIGAIG	ccccccca	Gaaaaataaa
4510	4580	4650	4720	•
GATTGCCCGA	GCCICGAGCA	CAGITITIAIT	TCCCTTTCCC	
4500	4560 4570	4640	4710	4770 4780
TGICGCACCT	CATGITIGGAA TITIAAICGCG	TGTAAGCAGA	AGACACAACG	CAIGAGGGA TACATATTIG
4490 4500	4560	4630 4640	4710 4710 AGACACAACG	4770
ATCGATAGAT TGTCGCACCT	CAUGITICGAA	TTACIGITTA IGIAAGCAGA		CAIGAGCGGA

4910 GCCCITICG IC

		18/19
70 ACCICIGAGA	140 GAAGAGAGGG	10 / 13
60 TGGAGAGAAA	130 TGGATGCAAT	
10 20 30 40 50 50 70 70 TOCAGAGAGAAA ACCICIGGGA	80 90 100 110 120 130 140 GGAAAGGGAA GGAGCAAGTTTAA GGGACGCTGT GAAGCAATCA TGGATGCAAT GAAGAAGGG	CGCCCAGC
40 ATCCTACAGG	110 GGGACGCIGI	180 GICTICGIIT
30 CAGAGCTGAG	100 GIGAAITITAA	150 160 170 180 CICIOCIGEIGEAGEA GIUTICGITT COCCEAGE
20 CGICGICGAC	90 GGAGCAAGCC	160 Techecieci
10 CIGCAGICAC	80 GGAAAGGGAA	150 CTCTGCTGTG

19/19




FIG.8

Docket No. 1038-1003 MIS:jb

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled				
NUCLEIC ACID VACCINES ENCODING G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS				
the specification of which	ch			
(check one)				
☐ is attached hereto.☒ was filed on July 1Application Number	PCT/CA98/00697	as United States Application No.	. or PCT International	
and was amended	on September 9, 1999	(if applicable)		
I'hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.				
_		Inited States Patent and Trademark ty as defined in Title 37, Code of		
Section 365(b) of any any PCT International a listed below and have a	foreign application(s application which des also identified below, PCT International ap	der Title 35, United States Code,) for patent or inventor's certificate signated at least one country other t by checking the box, any foreign a pplication having a filing date before	e, or Section 365(a) of than the United States, pplication for patent or	
Prior Foreign Application	on(s)		Priority Not Claimed	
(Number)	(Country)	(Day/Month/Year Filed)		
	(Country)			
(Number)	(Country)	(Day/Month/Year Filed)		
(Number)	(Country)	(Day/Month/Year Filed)	_	
PTO-SB-01 (9-95) (Modified)		P02/REV02 Patent and Trademark 0	Office-U.S. DEPARTMENT OF COMMER	

I hereby claim the benefit under application(s) listed below:	35 U.S.C. Section	119(e) of	any United	States provisional
(A - 1:1: O - :- N -)	(5)Page 20-1-1			
(Application Seria⊩No.)	(Filing Date)			
(Application Seria⊢No.)	(Filing Date)			
(Application Serial No.)	(Filing Date)			

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

08/896,442	July-18, 1997	Pending
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
PCT/CA98/00697	July 16, 1998	
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Michael I. Stewart (24,973)

Send Correspondence to: _

Sim & McBurney

6th Floor, 330 University Avenue

Toronto, Ontario Canada, M5G 1R7.

Direct Telephone Calls to: (name and telephone number)

(416) 595-1155

. Full name of sole or first inventor	
Xiaomao, Li	
Sole or first nyentor's signature	Date
	Teb. 22 Jow
Residence 🖊	
Thornhill, Ontario, Canada.	
Citizenship	
Canadian	
Post Office Address	
106 Glenmanor Way, Thornhill, Ontario, Canada, L4J 3E5.	

Full name of second inventor, if any Suryprakash Sambhara	
Second inventor's signature	Febog, 2000 Date
Residence	
Markham, Ontario, Canada. CAX	
Citizenship	
Canadian	
Post Office Address	
50 Harness Circle, Markham, Ontario, Canada, L3S 1Y1.	

Full name of third inventor, if any Michel H. Klein	
Third inventor's signature	Feb. 7 Jano
Residence Willowdale, Ontario, Canada.	100.100
Citizenship Canadian	
Post Office Address 16 Munro Boulevard, Willowdale, Ontario, Canada, M2P 1B9.	
Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
Full name of fifth inventor, it any	
ifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
full name of sixth inventor, if any	
Sixth inventor's signature	
	Date
Residence	
Citizenship	
Post Office Address	